Active, not recruitingPhase 3NCT05817812
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
Studying Hemophilia A
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swedish Orphan Biovitrum
- Principal Investigator
- Study Physician, MD, PhDSwedish Orphan Biovitrum AB
- Intervention
- Efanesoctocog alfa(drug)
- Enrollment
- 93 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2023 – 2026
Study locations (20)
- Investigational Site, Vienna, Austria
- Investigational Site, Zagreb, Croatia
- Investigational Site, Brno, Czechia
- Investigational Site, Prague, Czechia
- Investigational Site, Bordeaux, France
- Investigational Site, Le Kremlin-Bicêtre, France
- Investigational Site, Marseille, France
- Investigational Site, Strasbourg, France
- Investigational Site, Berlin, Germany
- Investigational Site, Frankfurt, Germany
- Investigational Site, Giessen, Germany
- Investigational Site, Hamburg, Germany
- Investigational Site, Athens, Greece
- Investigational Site, Dublin, Ireland
- Investigational Site, Catanzaro, Italy
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05817812 on ClinicalTrials.govOther trials for Hemophilia A
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05936580Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryOctapharma
- ACTIVE NOT RECRUITINGNCT07161687A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Pfizer
- RECRUITINGPHASE4NCT06864975Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)Runhui WU
- RECRUITINGPHASE1NCT06579144Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum
- RECRUITINGPHASE3NCT06738485Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCSL Behring
- RECRUITINGNCT06684314A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanSanofi
- RECRUITINGNCT07414511Hemophilia A Research ProgramUniversity of Washington
- RECRUITINGEARLY PHASE1NCT06345833Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded StudyUniversity of Minnesota